Results 241 to 250 of about 692,269 (276)

Small-molecule MDM2 inhibitors in clinical trials for cancer therapy

European Journal of Medicinal Chemistry, 2022
Fen-Er Chen
exaly  

Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with signaling attenuation; a step towards the next generation p53 activators

Bioorganic Chemistry, 2021
El Sayed H El Ashry, Mohamed M Said, Marwa M Abu-Serie   +2 more
exaly  

Synthesis of an MDM2 Inhibitor

Synfacts, 2013
openaire   +1 more source

MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)

Recent Patents on Anti-Cancer Drug Discovery, 2020
Joanna Jaszczewska-Adamczak, Jakub Witkowski, Rafał Rusiecki   +2 more
exaly  

Combination of immunotherapies with MDM2 inhibitors

2020
YANG DAJUN, ZHAI YIFAN, FANG DOUGLAS DONG, TANG QIUQIONG   +3 more
openaire   +3 more sources

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Proceedings of the National Academy of Sciences of the United States of America, 2008
Denzil Bernard, Ke Ding, Kenneth J. Pienta   +2 more
exaly  

PROCESSES FOR PREPARING A MDM2 INHIBITOR

2020
CAILLE SEBASTIEN, CORBETT MICHAEL, SMITH AUSTIN   +2 more
openaire   +2 more sources

The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy

European Journal of Medicinal Chemistry, 2018
Guochao Liao, Zhongqiu Liu, Lixin Duan
exaly  

SPIROPYRROLIDINES AS MDM2 INHIBITORS

2015
CHEN YI, DING QINGJIE JACK, SUN YANG-SHENG   +2 more
openaire   +4 more sources

Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument

Bioorganic and Medicinal Chemistry Letters, 2016
Sebastien Jeay, Achim Schlapbach, Andrea Vaupel   +2 more
exaly